News Johnson & Johnson

Equities

JNJ

US4781601046

Real-time Estimate Cboe BZX Other stock markets 02:22:27 2024-05-01 pm EDT			5-day change	1st Jan Change
151.1 ^USD	+4.49%		+1.66%	-3.66%

07:54pm	Sector Update: Health Care Stocks Advance Wednesday Afternoon	MT
06:23pm	Top Midday Stories: CVS Reports Q1 Earnings Miss, Lowers Outlook; ADP Q1 Earnings Top Estimates; J&J Proposes $6.5 Billion Settlement for Talc Lawsuits	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Advance Wednesday Afternoon	01:54pm	MT
Top Midday Stories: CVS Reports Q1 Earnings Miss, Lowers Outlook; ADP Q1 Earnings Top Estimates; J&J Proposes $6.5 Billion Settlement for Talc Lawsuits	12:23pm	MT
Johnson & Johnson Seeks EU Approval for Ulcerative Colitis, Crohn’s Disease Drug	10:39am	MT
Nasdaq, S&P 500 fall as investors take cover before Fed decision	10:35am	RE
Johnson & Johnson Announces $6.48 Billion Plan for Unit to Resolve Ovarian Cancer Talc Claims	10:17am	MT
Guggenheim Adjusts Johnson & Johnson's Price Target to $160 From $167	09:55am	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday	09:15am	MT
Sector Update: Health Care	08:47am	MT
Transcript : Johnson & Johnson - Special Call	08:00am
J&J subsidiary proposes paying about $6.48B over 25 years to settle talc ovarian cancer lawsuits	07:39am	AQ
Johnson & Johnson Announces $6.48 Billion Plan for Unit to Resolve Ovarian Cancer Talc Claims	07:37am	MT
Johnson & Johnson Announces Plan For Subsidiary to Resolve Ovarian Cancer Talc Claims	07:25am	MT
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization	06:32am	BU
J&J advances $6.475 billion settlement of talc cancer lawsuits	06:30am	RE
Johnson & Johnson to Consolidate Business Segments Under UK Brand	04:59am	MT
Alvotech And Teva's Selarsdi™ (ustekinumab-aekn), Biosimilar To Stelara® Approved By FDA	02:17am	AQ
Stryker lifts 2024 profit forecast on strong demand for medical devices, implants	06:11pm	RE
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...	Apr. 30
J&J, Bristol Myers lose challenges to US drug price negotiation program	Apr. 29	RE
Declared voting Results by Johnson & Johnson	Apr. 29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST